Evidence map›Paper›PMID 37926749›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2024

Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations.

R Balestrino, T Martone, M Toffoli, E Montanaro, M Fabbri, C A Artusi, A Romagnolo, M Zibetti, M Rizzone, S Goldwurm and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Early-Onset Parkinson's Disease: Unique Features and Management Approaches.Current neurology and neuroscience reports · 2025
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

R BalestrinoDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy. balestrino.roberta@hsr.it.
T MartoneDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
M ToffoliDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
E MontanaroDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
M FabbriDepartment of Neurosciences, Clinical Investigation Center 1436, NS-Park/FCRIN Network and NeuroToul COEN Center, Toulouse University Hospital, INSERM, University of Toulouse 3, Parkinson Toulouse Expert Center, Toulouse, France.
C A ArtusiDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
A RomagnoloDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
M ZibettiDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
M RizzoneDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
S GoldwurmDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
L LopianoDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
A H V SchapiraDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
University of Turin · ITUniversity College London · GBAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITFrench Clinical Research Infrastructure Network · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLevodopa-carbidopa intestinal gel infusion (LCIG) is a therapeutic option for advanced Parkinson disease (PD) patients with troublesome motor complications, unresponsive to conventional oral treatment. There is some evidence to suggest that the genetic background may influence the clinical presentation and rate of progression of PD. Whether the genetic background influences the outcome of device-assisted therapies is currently debated. Some studies have investigated the effectiveness of deep brain stimulation (DBS) in PD patients with different genetic background, while evidence is lacking regarding LCIG.

methodsA cohort of LCIG patients underwent genetic testing. The motor and neuropsychological outcomes of LCIG were retrospectively analyzed.

resultsFifty-six patients were analyzed, nine of them (15%) had at least one mutation/variant in a PD-associated gene: five GBA1, two SNCA, one LRRK2, one PRKN; 13 (23%) carried the BDNF Val66Met polymorphism. The mean duration of follow-up was 4.9 ± 2.6 years. There were no significant differences in motor or neuropsychological outcomes between patients with and without these gene mutations/variants. No cognitive worsening was observed at follow-up among GBA-PD patients, and they responded well to LCIG in terms of motor symptoms.

conclusionsOverall, we observed a significant benefit in terms of motor complications in our cohort, including patients carrying genetic mutations/variants. Due to the small sample and limited number of patients carrying genetic mutations/variants, no definitive conclusions can be drawn yet on the genotype impact on LCIG outcome. A careful selection of patients, regardless of the genetic background, is pivotal for an optimal outcome of LCIG.

Indexed as

CarbidopaParkinson DiseaseAntiparkinson AgentsDrug CombinationsGelsHumansLevodopaMutationRetrospective StudiesAntiparkinson AgentsCarbidopaDrug CombinationsGelsLevodopaBDNFDevice-assisted therapiesGBAGeneticsLevodopa carbidopa intestinal gel infusionParkinson disease

Identifiers

PMID37926749
OpenAlexW4388399094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.